LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Aandelen Lijst・uniQure NV

uniQure NV

Gesloten

25.12 0.72

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

24.79

Max

25.48

Belangrijke statistieken
By Trading Economics
Inkomsten	-16M -54M
Verkoop	-2M 3.6M
EPS	-0.73
Winstmarge	-1,502.948
Werknemers	221
EBITDA	13M -36M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+54.27% upside

Dividenden
By Dow Jones
Volgende Winsten	28 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	265M 1.6B
Vorige openingsprijs	24.4
Vorige sluitingsprijs	25.12

uniQure NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 mrt 2026, 13:13 UTC

Belangrijke Marktbewegers

UniQure Down in Premarket as FDA Says Huntington's Gene-Therapy Data Falls Short

9 jan 2026, 15:14 UTC

Belangrijke Marktbewegers

UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment

3 nov 2025, 13:34 UTC

Belangrijke Marktbewegers

UniQure Shares Sink After Negative FDA Response to Huntington's Disease Treatment

24 sep 2025, 18:51 UTC

Winsten

These Stocks Are Moving the Most Today: Alibaba, Micron, Lithium Americas, Freeport-McMoRan, uniQure, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

uniQure NV Prognose

Koersdoel

By TipRanks

54.27% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 38.8 USD 54.27%

Hoogste 95 USD

Laagste 9 USD

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor uniQure NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan uniQure NV - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over uniQure NV

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.